Seagen shareholders approve $43B acquisition by Pfizer

Seagen, a Bothell biotech company, is set to be acquired by Pfizer Pharmaceuticals following a shareholder vote on May 30. The $43 billion purchase is expected to provide both Seagen and Pfizer with opportunities to expand oncology research, treatment and medication. The acquisition was approved by an 88% majority of shareholders.


Pfizer plans to add Seagen’s four cancer treatments to its existing 24 cancer medications to increase offerings for patients.


“The affirmative vote brings us one step closer to joining with Pfizer to accelerate our ability to deliver transformative cancer medicines to more patients in need around the world,” said David Epstein, CEO of Seagen.


READ THE STORY at Puget Sound Business Journal »